The necessity for additional assessment of surveillance indicators of the timeliness of contacting a medical institution with suspected human anthrax in Azerbaijan
pdf

Keywords

EIDSS
Anthrax
surveillance indicators
timeliness of initial visit to the doctor

How to Cite

RASULZADE, Z., ISMAYILOVA, R. and MURSALOVA, N. (2023) “The necessity for additional assessment of surveillance indicators of the timeliness of contacting a medical institution with suspected human anthrax in Azerbaijan”, One Health & Risk Management , p. 60. Available at: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/640 (Accessed: 8July2025).

Abstract

Introduction. Cutaneous anthrax in Azerbaijan is an endemic disease among people, particularly in regions with active cattle breeding. Over the period from 2018 to 2022, an average of 12-15 cases were recorded annually, primarily among the rural population. Notably, in 2022, the number of confirmed cases experienced a significant increase. Surveillance for anthrax, along with other infectious diseases, is conducted through the electronic surveillance system for infectious diseases (EIDSS).

Aim. To assess the reason for the increase in the number of anthrax cases in Azerbaijan, utilizing surveillance timeliness indicators.

Material and methods. We conducted an analysis of the electronic database in EIDSS of the Ministry of Health, focusing on initially reported cases of cutaneous anthrax among humans for the year 2022. The surveillance system was assessed, incorporating timeliness indicators, such as the date when the patient first sought care, the urgency of notification, case entry, initiation of epidemiological investigations, and the completeness of information in the fields related to collected and tested samples. The conventionally assumed threshold value for surveillance indicators is 80% of all cases reported to the system. Laboratory confirmation of samples from suspected cases is performed using both the PCR method and bacteriological methods. Methodological documents used for the evaluation included the “Rules for the Surveillance and Control of Especially Dangerous Infections” (Ministry of Health, Azerbaijan) and the “Updated Guidelines for Evaluating Public Health Surveillance Systems” (CDC, Atlanta).

Results. In 2022, a total of 58 human cases of cutaneous anthrax were reported in EIDSS, with 25 cases confirmed by positive laboratory results. Further investigation into cases with negative laboratory results revealed that some patients had self-administered antibiotics and ointments before seeking medical attention. Despite clinical symptoms being present among cases with negative test results (e.g., papules in 91% of cases) and significant risk factors (such as handling meat in 24.2% of cases), there was a notable difference in the timeliness of seeking medical care (p<0.05). While the average time from the onset of symptoms to the first medical visit for confirmed cases was 4.5 days, it was 7.8 days for cases with negative laboratory results. The timeliness of emergency notification, case entry into EIDSS, and the initiation of epidemiological investigations for both confirmed cases and cases with negative test results did not significantly differ and exceeded the threshold level of 80% for all reported cases, as required in the country. The adequacy and completeness of filling in the fields of the laboratory module scored 100%. In the context of a One Health approach investigation, no cases were reported in EIDSS among animals.

Conclusions. The evaluated timeliness indicators are equally high and exceeded the threshold level for both confirmed cases and cases with negative laboratory results. However, the revealed late appeal of the population with suspected anthrax and self-administration of antibiotics requires the adoption of appropriate measures to educate the population about the risk factors, prevention and effectiveness of timely contacting a medical institution.

pdf

|Views: 81| |pdf Downloads: 31|


pdf
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Downloads

Download data is not yet available.

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370